These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15948811)

  • 21. The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.
    Loguercio C; Federico A; Masarone M; Torella R; Blanco Cdel V; Persico M
    Am J Gastroenterol; 2008 Dec; 103(12):3159-66. PubMed ID: 18786125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors for hepatitis C fibrosis: a prospective study of United States veterans compared with nonveterans.
    Kayali Z; Tan S; Shinkunas L; Voigt M; LaBrecque DR; Stapleton JT; Brown KE; Schmidt WN
    J Viral Hepat; 2007 Jan; 14(1):11-21. PubMed ID: 17212639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease.
    Masarone M; La Mura V; Bruno S; Gaeta GB; Vecchione R; Carrino F; Moschella F; Torella R; Persico M
    J Viral Hepat; 2007 Oct; 14(10):714-20. PubMed ID: 17875006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there any non-invasive marker replace the needle liver biopsy predictive for liver fibrosis, in patients with chronic hepatitis?
    Vardar R; Vardar E; Demiri S; Sayhan SE; Bayol U; Yildiz C; Postaci H
    Hepatogastroenterology; 2009; 56(94-95):1459-65. PubMed ID: 19950810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The impact of coexisting diseases on the course of chronic hepatitis C].
    Kryczka W; Zarebska-Michaluk D; Chrapek M
    Przegl Epidemiol; 2005; 59(2):405-10. PubMed ID: 16190547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
    Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection.
    Cross TJ; Quaglia A; Hughes S; Joshi D; Harrison PM
    J Viral Hepat; 2009 Jul; 16(7):492-9. PubMed ID: 19200134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C.
    Snyder N; Nguyen A; Gajula L; Soloway R; Xiao SY; Lau DT; Petersen J
    Clin Chim Acta; 2007 Jun; 381(2):119-23. PubMed ID: 17442291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.
    Barreiro P; Martín-Carbonero L; Núñez M; Rivas P; Morente A; Simarro N; Labarga P; González-Lahoz J; Soriano V
    Clin Infect Dis; 2006 Apr; 42(7):1032-9. PubMed ID: 16511772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C.
    Vidali M; Occhino G; Ivaldi A; Rigamonti C; Sartori M; Albano E
    Am J Gastroenterol; 2008 Jan; 103(1):147-53. PubMed ID: 18184121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with hepatic fibrosis in patients with chronic hepatitis C: a retrospective study of a large cohort of U.S. patients.
    Hu SX; Kyulo NL; Xia VW; Hillebrand DJ; Hu KQ
    J Clin Gastroenterol; 2009 Sep; 43(8):758-64. PubMed ID: 19238091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression of liver fibrosis among injection drug users with chronic hepatitis C.
    Wilson LE; Torbenson M; Astemborski J; Faruki H; Spoler C; Rai R; Mehta S; Kirk GD; Nelson K; Afdhal N; Thomas DL
    Hepatology; 2006 Apr; 43(4):788-95. PubMed ID: 16557548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age.
    Selzner N; Girgrah N; Lilly L; Guindi M; Selzner M; Therapondos G; Adeyi O; McGilvray I; Cattral M; Greig PD; Grant D; Levy G; Renner EL
    Liver Transpl; 2008 Dec; 14(12):1778-86. PubMed ID: 19025914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rebiopsy in patients with untreated hepatitis C: a useful procedure.
    Khouri ST; Perez RM; de Oliveira PM; Figueiredo VM; Barbosa DV; Lanzoni VP; Silva AE; Ferraz ML
    J Clin Gastroenterol; 2006 Apr; 40(4):347-52. PubMed ID: 16633108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies.
    Kage M; Shimamatu K; Nakashima E; Kojiro M; Inoue O; Yano M
    Hepatology; 1997 Apr; 25(4):1028-31. PubMed ID: 9096615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis.
    Bugianesi E; Marchesini G; Gentilcore E; Cua IH; Vanni E; Rizzetto M; George J
    Hepatology; 2006 Dec; 44(6):1648-55. PubMed ID: 17133473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis.
    Olmez OF; Gurel S; Yilmaz Y
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):461-5. PubMed ID: 19940783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis.
    Tsochatzis E; Papatheodoridis GV; Manesis EK; Kafiri G; Tiniakos DG; Archimandritis AJ
    Aliment Pharmacol Ther; 2008 Jan; 27(1):80-9. PubMed ID: 17919273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Replacement of hystological findings: serum hyaluronic acid for fibrosis, high-sensitive C-reactive protein for necroinflamation in chronic viral hepatitis.
    Yilmaz S; Bayan K; Tüzün Y; Dursun M; Kaplan A; Ozmen S; Canoruç F; Akkuş Z
    Int J Clin Pract; 2007 Mar; 61(3):438-43. PubMed ID: 17313611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.